The novel vaccine adjuvant CAF®09b is formulated by electrostatically complexing the TLR3 agonist poly(I:C) with a cationic liposomal delivery system comprising dimethyldioctadecylammonium bromide (DDA) and C-type lectin receptor agonist monomycoloyl glycerol (MMG), and was developed for vaccines against viral infections [11,12] and cancer [13]. The gene discussed is TLR3; the disease is viral infectious disease.